NKTR

Nektar Therapeutics

0.68 USD
-0.00 (-0.50%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Nektar Therapeutics stock is up 33.14% since 30 days ago. The next earnings date is Mar 8, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 50% of the previous 29 February’s closed higher than January.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, which is in phase 3 clinical trial to treat metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, squamous cell carcinomas of the head and neck, and adjuvant melanoma. It is also developing NKTR-358, a cytokine Treg stimulant, in phase 2 clinical trial for the treatment of systemic lupus erythematosus